SCHEMBL5138353

SCHEMBL5138353

NCC1CCC(c2nc(-c3ccc4ccc(Oc5ccccc5)nc4c3)c3cncnn23)CC1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 17/20 0.53
IGF1R P08069 3/20 0.41
INSR P06213 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399573 0.84 TNK2 (0.76) TNK2IGF1RINSR
SCHEMBL5138490 0.83 TNK2 (0.45) TNK2IGF1RINSR
SCHEMBL398950 0.76 TNK2 (0.76) TNK2IGF1R
SCHEMBL401942 0.74 TNK2 (0.74) TNK2IGF1RINSR
SCHEMBL5141560 0.71 IGF1R (0.47) TNK2IGF1RINSR
SCHEMBL399626 0.71 TNK2 (0.64) TNK2IGF1RINSR
SCHEMBL5082715 0.71 FLT3 (0.42) TNK2INSR
Carbamic Acid SCHEMBL4062520 0.70 IGF1R (0.65) TNK2IGF1RINSR
SCHEMBL400022 0.70 IGF1R (0.81) TNK2IGF1RINSR
SCHEMBL5141558 0.69 IGF1R (0.57) TNK2IGF1RINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979002-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI Pharmaceuticals, Inc. (US) 2008-10-15 EP disclosed
WO-2008076143-A1 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2008-06-26 WO disclosed
WO-2007075554-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2007-07-05 WO disclosed